<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680301</url>
  </required_header>
  <id_info>
    <org_study_id>CR-16-019</org_study_id>
    <nct_id>NCT02680301</nct_id>
  </id_info>
  <brief_title>Topical Steroid Formulation and Wet Wraps</brief_title>
  <official_title>Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seton Healthcare Family</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seton Healthcare Family</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to

        1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream
           formulation in patients with moderate to severe atopic dermatitis

        2. The relative patient/subject acceptance and adherence will also be compared between the
           two wet wrap types
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will examine the effectiveness of wet wraps with topical
      steroids in different formulations for patients with a history of atopic dermatitis who are
      experiencing an acute flare. A validated clinical tool such Investigator's Global Assessment
      (IGA) will be used in order to assess severity of the condition as well as demonstrate the
      appropriateness of using wet wrap therapy as a treatment modality. IGA will measure intensity
      of the atopic dermatitis regarding erythema, lichenification, swelling and excoriation as
      well as subjective symptoms of the patient on a numeric scale. The treating clinician will be
      asked to rate their assessment before and after therapy.

      Patients will be asked to apply a topical steroid in a cream formulation to one extremity and
      then apply the same topical steroid in an ointment formulation to the other using the wet
      wrap technique. One of the investigators or nursing staff will provide detailed instructions
      to the patient and parents on how to perform the wet dressing (this is already routinely done
      for patients initiating wet wrap therapy in the pediatric dermatology clinic). Patients will
      also be given a sealed and coded envelope containing instructions to apply one steroid
      formulation to the right extremity and the other to the left. In this manner the providers
      will be blinded to treatment modality during the follow-up visit. Only the research
      coordinator will have access to the envelope code key. An additional handout will also be
      provided to reinforce appropriate treatment technique. After several days (3-5) the patient
      will return to the dermatology clinic for a nurse visit and evaluation of any improvement of
      the affected areas as well as comparison of improvement of the right and left extremities.
      The physician investigator will examine the patient and measure improvement using the IGA.
      Detailed photos of the affected areas will also be taken. After a certain number of patients
      have enrolled in the study and completed it, the de-identified data will be examined by a
      statistician for comparison. Other studies evaluating the effectiveness of wet wraps have
      commonly had 40-50 patients enrolled which will likely be the target of this study. The
      statistician will compare the IGA before and after treatment on each side to allow for
      interpretation of the data. Stratification of data may include ages and/or severity (moderate
      vs severe).

      Patient Oriented Eczema Measure (POEM) and/or a Quality of Life (QoL) index will also be
      provided to determine the patient's point of view regarding their management using validated
      tools. They will also be asked their opinion regarding if one side was better controlled than
      the other, if at all, as well as their personal preference for treatment of choice.

      Compliance will be determined by weighing the medication before and after each visit and a
      medication calendar.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis</measure>
    <time_frame>3-5 days</time_frame>
    <description>Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear; 2=mild disease; 3=moderate disease; 4=severe disease; 5- very severe disease
Lower scores represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Efficacy</measure>
    <time_frame>3-5 days</time_frame>
    <description>Patient report of which topical steroid formulation was more effective</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients Adhering to Treatment Protocol</measure>
    <time_frame>3-5 days</time_frame>
    <description>Patient-reported adherence to wet-wrap protocol. Medication logs were used to evaluate adherence to the treatment protocol for both steroid formulations. Patents were determined to be adhering to the protocol if the number of wet-wraps for each study arm (cream or ointment) were the same. Because the total number of wraps varied between patients (the protocol required 1-2 wraps per day for 3-5 days), we reviewed medication logs to determine that each patient completed an equivalent number of ointment and cream wraps.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Ointment Right/Cream Left</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ointment Left/Cream Right</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% triamcinolone CREAM</intervention_name>
    <description>Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.</description>
    <arm_group_label>Ointment Left/Cream Right</arm_group_label>
    <arm_group_label>Ointment Right/Cream Left</arm_group_label>
    <other_name>topical steroid cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% triamcinolone OINTMENT</intervention_name>
    <description>Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.</description>
    <arm_group_label>Ointment Left/Cream Right</arm_group_label>
    <arm_group_label>Ointment Right/Cream Left</arm_group_label>
    <other_name>topical steroid ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients between the ages of 3-17 experiencing a symmetric, bilateral flare of atopic
             dermatitis

          2. The flares must reach a certain threshold for inclusion based on the investigator's
             global assessment scale

        Exclusion Criteria:

          1. Systemic infection or bacterial skin infections

          2. Eczema herpeticum

          3. Evidence of suppression of the Hypothalamic-Pituitary-Adrenal axis

          4. Non-English or Non-Spanish speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton: Dell Children's Medical Center: Specially for Childrens Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Specially for Children Dermatology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008 Oct;122(4):812-24. doi: 10.1542/peds.2007-2232. Review.</citation>
    <PMID>18829806</PMID>
  </reference>
  <reference>
    <citation>Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D, Goeteyn M, de Waard-van der Spek FB. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014 Jun;70(6):1076-82. doi: 10.1016/j.jaad.2014.01.898. Epub 2014 Mar 31.</citation>
    <PMID>24698702</PMID>
  </reference>
  <reference>
    <citation>Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006 Apr;154(4):579-85. Review.</citation>
    <PMID>16536797</PMID>
  </reference>
  <reference>
    <citation>Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: A retrospective study. J Am Acad Dermatol. 2009 May;60(5):792-800. doi: 10.1016/j.jaad.2008.12.043.</citation>
    <PMID>19389521</PMID>
  </reference>
  <reference>
    <citation>Oranje AP, Devillers AC, Kunz B, Jones SL, DeRaeve L, Van Gysel D, de Waard-van der Spek FB, Grimalt R, Torrelo A, Stevens J, Harper J. Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1277-86. Review.</citation>
    <PMID>17062046</PMID>
  </reference>
  <reference>
    <citation>Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004 Dec;140(12):1513-9. Erratum in: Arch Dermatol. 2005 Mar;141(3):381.</citation>
    <PMID>15611432</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <results_first_submitted>June 28, 2018</results_first_submitted>
  <results_first_submitted_qc>August 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2018</results_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seton Healthcare Family</investigator_affiliation>
    <investigator_full_name>Lucia Zoraida Diaz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Wet Wraps</keyword>
  <keyword>Topical Steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02680301/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ointment Right/Cream Left</title>
          <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
0.1% triamcinolone CREAM: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
0.1% triamcinolone OINTMENT: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.</description>
        </group>
        <group group_id="P2">
          <title>Ointment Left/Cream Right</title>
          <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
0.1% triamcinolone CREAM: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
0.1% triamcinolone OINTMENT: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ointment Right/Cream Left</title>
          <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
0.1% triamcinolone CREAM: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
0.1% triamcinolone OINTMENT: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.</description>
        </group>
        <group group_id="B2">
          <title>Ointment Left/Cream Right</title>
          <description>Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
0.1% triamcinolone CREAM: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
0.1% triamcinolone OINTMENT: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.14" spread="3.88"/>
                    <measurement group_id="B2" value="7.29" spread="3.27"/>
                    <measurement group_id="B3" value="7.77" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis</title>
        <description>Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear; 2=mild disease; 3=moderate disease; 4=severe disease; 5- very severe disease
Lower scores represent a better outcome.</description>
        <time_frame>3-5 days</time_frame>
        <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cream</title>
            <description>Extremity that was treated with wet wraps and 0.1% triamcinolone in cream formulation</description>
          </group>
          <group group_id="O2">
            <title>Ointment</title>
            <description>Extremity that was treated with wet wraps and 0.1% triamcinolone in cream formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis</title>
          <description>Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear; 2=mild disease; 3=moderate disease; 4=severe disease; 5- very severe disease
Lower scores represent a better outcome.</description>
          <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.717" spread="0.65"/>
                    <measurement group_id="O2" value="0.589" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Wilcoxon sign- rank test values with ranks from change in cream efficacy ratings minus change in ointment efficacy ratings.</non_inferiority_desc>
            <p_value>0.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Efficacy</title>
        <description>Patient report of which topical steroid formulation was more effective</description>
        <time_frame>3-5 days</time_frame>
        <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Efficacy</title>
          <description>Patient report of which topical steroid formulation was more effective</description>
          <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cream</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ointment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Difference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Adhering to Treatment Protocol</title>
        <description>Patient-reported adherence to wet-wrap protocol. Medication logs were used to evaluate adherence to the treatment protocol for both steroid formulations. Patents were determined to be adhering to the protocol if the number of wet-wraps for each study arm (cream or ointment) were the same. Because the total number of wraps varied between patients (the protocol required 1-2 wraps per day for 3-5 days), we reviewed medication logs to determine that each patient completed an equivalent number of ointment and cream wraps.</description>
        <time_frame>3-5 days</time_frame>
        <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Adhering to Treatment Protocol</title>
          <description>Patient-reported adherence to wet-wrap protocol. Medication logs were used to evaluate adherence to the treatment protocol for both steroid formulations. Patents were determined to be adhering to the protocol if the number of wet-wraps for each study arm (cream or ointment) were the same. Because the total number of wraps varied between patients (the protocol required 1-2 wraps per day for 3-5 days), we reviewed medication logs to determine that each patient completed an equivalent number of ointment and cream wraps.</description>
          <population>Patients ages 3 to 17 experiencing a symmetric, bilateral flare of atopic dermatitis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ointement</title>
          <description>0.1% triamcinolone OINTMENT with wet-wrap dressing</description>
        </group>
        <group group_id="E2">
          <title>Cream</title>
          <description>0.1% triamcinolone CREAM with wet-wrap dressing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katherine Sebastian</name_or_title>
      <organization>Seton Family of Hospitals/Ascension</organization>
      <phone>801-598-2484</phone>
      <email>krsebastian@ascension.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

